C3 Glomerulopathy and ICGN: OMS906 Study

We are testing a new drug called OMS906 in patients with C3 Glomerulopathy or Idiopathic Immune Complex-Mediated Glomerulonephritis. The study aims to evaluate the safety and early effects of this treatment on kidney function.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Oms906

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Lithuanian University of Health Sciences
Lithuanian University of Health Sciences, Hospital Kauno Klinikos
Kaunas, Lithuania
Vilnius University Hospital Santaros Klinikos
Nephrology center (Corps D, 1 Floor)
Vilnius, Lithuania
SPZOZ Centralny Szpital Kliniczny Uniwersytetu Medycznego w Łodzi
Klinika Nefrologii, Hipertensjologii i Transplantologii Nerek
Łódź, Poland
Sponsor: Omeros Corp.
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.